Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide BID versus placebo for gastric emptying during hypoglycaemia in type 2 diabetes
ACTRN12622001506785Phase 3Recruiting
- Sponsor
- Royal Adelaide Hospital
- Start
- Jun 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Royal Adelaide Hospital. Primary endpoint: Change in gastric emptying between hypoglycaemia and euglycaemia after exenatide versus placebo. Started Jun 2020; status: recruiting.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12622001506785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001506785.